^
Chr del(17p)
CLL
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
EHA 2022 - 2 weeks - (New C3)
TP53 mutation
CLL
venetoclax + obinutuzumab
Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
TP53 mutation
CLL
venetoclax
Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
Chr del(17p)
CLL
venetoclax
Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
Chr del(17p)
CLL
acalabrutinib
Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
TP53 mutation
CLL
acalabrutinib
Sensitive: A1 - Approval
EHA 2022 - 2 weeks - (New C3)
BTK C481
CLL
LOXO-305
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
IGH mutation
CLL
iFCG
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
SF3B1 mutation
CLL
venetoclax
Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
BCL2 D103Y
CLL
venetoclax + obinutuzumab
Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
BCL2 G101V
CLL
venetoclax + rituximab
Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
BCL2 G101V
CLL
venetoclax + obinutuzumab
Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
BCL2 D103Y
CLL
venetoclax + rituximab
Resistant: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
IGH mutation
CLL
venetoclax
Sensitive: C3 – Early Trials
EHA 2022 - 2 weeks - (New C3)
CD20 positive
CLL
Truxima (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
CLL
rituximab + ibrutinib
Sensitive: A1 - Approval
Chr del(17p)
CLL
venetoclax + obinutuzumab
Sensitive: A1 - Approval
No biomarker
CLL
venetoclax + obinutuzumab
Sensitive: A1 - Approval
No biomarker
CLL
orelabrutinib
Sensitive: A1 - Approval
CD20 expression
CLL
rituximab-arrx
Sensitive: A1 - Approval
No biomarker
CLL
Truxima (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
CLL
Rixathon (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
CLL
Ruxience (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
CLL
venetoclax + rituximab
Sensitive: A1 - Approval
No biomarker
CLL
zanubrutinib
Sensitive: A1 - Approval
No biomarker
CLL
ibrutinib
Sensitive: A1 - Approval
No biomarker
CLL
ibrutinib + obinutuzumab
Sensitive: A1 - Approval
No biomarker
CLL
obinutuzumab
Sensitive: A1 - Approval
No biomarker
CLL
rituximab
Sensitive: A1 - Approval
No biomarker
CLL
ofatumumab
Sensitive: A1 - Approval
CD20 positive
CLL
rituximab
Sensitive: A1 - Approval
No biomarker
CLL
venetoclax
Sensitive: A1 - Approval
No biomarker
CLL
rituximab / hyaluronidase
Sensitive: A1 - Approval
Chr del(17p)
CLL
ibrutinib
Sensitive: A1 - Approval
No biomarker
CLL
obinutuzumab + acalabrutinib
Sensitive: A1 - Approval
No biomarker
CLL
obinutuzumab
Sensitive: A1 - Approval
No biomarker
CLL
acalabrutinib
Sensitive: A1 - Approval
Chr del(17p)
CLL
rituximab + idelalisib
Sensitive: A1 - Approval
TP53 mutation
CLL
rituximab + idelalisib
Sensitive: A1 - Approval
No biomarker
CLL
alemtuzumab
Sensitive: A1 - Approval
TP53 mutation
CLL
idelalisib + ofatumumab
Sensitive: A1 - Approval
Chr del(17p)
CLL
idelalisib + ofatumumab
Sensitive: A1 - Approval
No biomarker
CLL
rituximab + idelalisib
Sensitive: A1 - Approval
No biomarker
CLL
duvelisib
Sensitive: A1 - Approval
CD20 positive
CLL
Ruxience (rituximab biosimilar)
Sensitive: A1 - Approval
No biomarker
CLL
bendamustine
Sensitive: A1 - Approval
No biomarker
CLL
bendamustine RTD
Sensitive: A1 - Approval
No biomarker
CLL
PCR
Sensitive: A2 - Guideline
Chr del(17p)
CLL
ofatumumab
Sensitive: A2 - Guideline
No biomarker
CLL
FCR
Sensitive: A2 - Guideline
TP53 mutation
CLL
rituximab + alemtuzumab
Sensitive: A2 - Guideline
Chr del(17p)
CLL
rituximab
Sensitive: A2 - Guideline
TP53 mutation
CLL
venetoclax + rituximab
Sensitive: A2 - Guideline
Chr del(17p)
CLL
venetoclax + rituximab
Sensitive: A2 - Guideline
TP53 mutation
CLL
zanubrutinib
Sensitive: A2 - Guideline
Chr del(17p)
CLL
zanubrutinib
Sensitive: A2 - Guideline
No biomarker
CLL
rituximab + lenalidomide
Sensitive: A2 - Guideline
No biomarker
CLL
rituximab + idelalisib
Sensitive: A2 - Guideline
Chr del(11q)
CLL
ibrutinib
Sensitive: A2 - Guideline
Chr del(11q)
CLL
rituximab
Resistant: A2 - Guideline
TP53 mutation
CLL
ibrutinib
Sensitive: A2 - Guideline
TP53 mutation
CLL
ofatumumab
Resistant: A2 - Guideline
TP53 mutation
CLL
idelalisib
Sensitive: A2 - Guideline
Chr del(17p)
CLL
idelalisib
Sensitive: A2 - Guideline
IGH mutation
CLL
ibrutinib
Sensitive: A2 - Guideline
IGH mutation
CLL
obinutuzumab
Sensitive: A2 - Guideline
IGH mutation
CLL
venetoclax + obinutuzumab
Sensitive: A2 - Guideline
No biomarker
CLL
chlorambucil
Sensitive: A2 - Guideline
No biomarker
CLL
CD20 inhibitor + bendamustine
Sensitive: A2 - Guideline
TP53 mutation
CLL
lenalidomide
Sensitive: A2 - Guideline
TP53 mutation
CLL
rituximab + lenalidomide
Sensitive: A2 - Guideline
Chr del(17p)
CLL
lenalidomide
Sensitive: A2 - Guideline
Chr del(17p)
CLL
rituximab + lenalidomide
Sensitive: A2 - Guideline
No biomarker
CLL
lenalidomide
Sensitive: A2 - Guideline
TP53 deletion
CLL
idelalisib
Sensitive: A2 - Guideline
No biomarker
CLL
idelalisib
Sensitive: A2 - Guideline
No biomarker
CLL
rituximab + alemtuzumab
Sensitive: A2 - Guideline
TP53 deletion
CLL
ibrutinib
Sensitive: A2 - Guideline
TP53 deletion
CLL
rituximab
Sensitive: A2 - Guideline
TP53 mutation
CLL
rituximab
Sensitive: A2 - Guideline
Chr del(17p)
CLL
alemtuzumab
Sensitive: A2 - Guideline
TP53 mutation
CLL
alemtuzumab
Sensitive: A2 - Guideline
TP53 mutation
CLL
pembrolizumab + nivolumab + ibrutinib
Sensitive: A2 - Guideline
BTK C481S
CLL
acalabrutinib
Resistant: A2 - Guideline
IGH mutation
CLL
FCR
Sensitive: A2 - Guideline
Chr del(17p)
CLL
pembrolizumab
Sensitive: A2 - Guideline
Chr del(17p)
CLL
nivolumab
Sensitive: A2 - Guideline
Chr del(11q)
CLL
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
Chr del(17p)
CLL
duvelisib
Sensitive: A2 - Guideline
Chr del(17p)
CLL
obinutuzumab
Sensitive: A2 - Guideline
TP53 mutation
CLL
pembrolizumab + ibrutinib
Sensitive: A2 - Guideline
TP53 mutation
CLL
pembrolizumab
Sensitive: A2 - Guideline
TP53 mutation
CLL
nivolumab
Sensitive: A2 - Guideline
TP53 mutation
CLL
duvelisib
Sensitive: A2 - Guideline
TP53 mutation
CLL
obinutuzumab
Sensitive: A2 - Guideline
TP53 mutation
CLL
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
Chr del(17p)
CLL
rituximab + alemtuzumab
Sensitive: A2 - Guideline
No biomarker
CLL
OFAR
Sensitive: A2 - Guideline
No biomarker
CLL
R-CVAD
Sensitive: A2 - Guideline
No biomarker
CLL
EPOCH-R
Sensitive: A2 - Guideline
No biomarker
CLL
R-CHOP
Sensitive: A2 - Guideline
No biomarker
CLL
BR
Sensitive: A2 - Guideline
No biomarker
CLL
BR + ibrutinib
Sensitive: A2 - Guideline
No biomarker
CLL
BR + idelalisib
Sensitive: A2 - Guideline
TP53 wild-type
CLL
zanubrutinib
Sensitive: A2 - Guideline
Chr del(11)(q22.3)
CLL
ibrutinib
Sensitive: B - Late Trials